Clinical Trials

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB.

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time samples of the skin and swab samples of stool will be collected. All subjects will be asked to complete questionnaires about their skin care regimen and dietary habits.

PEDISTAD is an observational study to assess the features of children with moderate to severe atopic dermatitis, also called eczema,whose disease is not adequately controlled with topical therapies (creams orlotions) or when those therapies are not medically advisable.

Participants in this non-interventional study will be treated in the usual way for their conditions and will not undergo extra tests. The study will document how atopic dermatitis and other diseases linked to atopic dermatitis changes over time and will also investigate the influence of routine clinical practice on clinical results to understand how atopic dermatitis affects children and their caregivers in their daily lives. There is an optional, additional study that will also enroll subjects for the collection of research specimens during regularly scheduled clinic appointments for biomarker analysis.

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience.

Additionally, researchers are interested in:

• Observing how skin condition treatments work and understand side effects caused by these medicines and how these are managed
• Identifying other types of conditions associated with skin disorders
• Collecting patient reported outcomes to better understand the patient perspective and feelings patients have about having a skin condition
• Assessing the impact of Patient Support Programs for individuals with skin conditions and how these programs affect skin condition outcomes
• Creating a “Biorepository Specimen Bank” with blood and saliva samples

Patients age 6-17 years old with moderate to severe plaque psoriasis with at least one of: facial/scalp, genital, palm/sole, axillary involvement, candidate for systemic treatment or photo therapy or photochemotherapy.

The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting.

The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris.

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.

This research is being done to determine the impact of dupilumab on sleep in children suffering from AD. Dupilumab is an FDA approved drug that can improve your eczema, and is injected under the skin once every other week for patients weighing more than 30kg (about 66 lbs) or once a month for patients weighing less than 30kg (about 66 lbs).

If you agree to take part in the study, you will complete a screening visit at a Lurie Children’s location, NMH, or Abbott Hall after which you will come to Lurie Children’s Hospital, NMH, or Abbott Hall for two scheduled overnight stays where sleep studies will be performed. The screening visit may be completed remotely, and a watch to be used in this study will be mailed to your address. The study drug will first be given at the end of the pre-treatment visit. During the pre-treatment study visit, you will be trained on how to inject the study drug at home.

During weeks 1-12, you will continue injections of the study drug at home. Your study doctor or staff may contact you virtually during this period to check-in.

This research is being done to determine the impact of dupilumab on itch in children and adults suffering from itch disorders. Dupilumab is an FDA approved drug for eczema. Dupilumab is injected under the skin once every other week for patients weighing more than 30kg (about 66 lbs.) or once a month for patients weighing less than 30kg (about 66 lbs.).

We expect that your child will be in this research study for about 2 years (26 months, or 104 weeks). There will be an observational period of 8 weeks, followed by a treatment period of 16 weeks in which your child will receive dupilumab. This may be followed by a 20-month long-term extension period for those who qualify and wish to continue.

Your child will attend up to seven (7) visits in person during the observation period and 16-week open label phase period. The screening visit will take approximately 3 hours, and all other in person visits will take approximately 1-2 hours to complete.

The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with radiation treatment in 2 fractions of 4 Gy (units of radiation absorbed by the patient) (total 8 Gy) over 2 days to the same designated lesions. In addition, subjects will have two skin biopsies during the screening period and again at the same locations at week 8.

The purpose of this study is to collect characteristic data from patients with medical conditions affecting hair health using medical records and surveys.

The main benefit of being in this study is to provide future benefit to patients with acquired and congenital hair disorders and the providers who care for them by adding to our understanding of normal hair physiology, causes and mechanisms of disease, clinical and molecular features, natural history, and treatment outcomes.

This research is being done to test the safety and efficacy of the study drug, upadacitinib, compared to a placebo (a treatment with no active properties) for the treatment of HS patients. Upadacitinib has been approved for specific medical conditions, but not approved for HS. The use of the study drug is investigational (experimental) for the purposes of this study.

The purpose of this study is to assess the effectiveness and safety of Upadacitinib compared with Dupilumab for adults who have responded poorly to Dupilumab after using the medication for at least 4 months. Upadacitinib, started at 15 mg a day and increased to 30 mg a day based on clinical response, will help inform the clinical management of adults with moderate to severe Atopic Dermatitis (AD) who have an inadequate response to Dupilumab.

The purpose of this research study is to assess the safety and effectiveness of lutikizumab compared with a placebo for the treatment of signs and symptoms of moderate to severe Hidradenitis Suppurativa (HS) in adults and adolescents 16 years of age or older.

The purpose of this study is to learn more about the effect of the study drug on chronic and/or subacute cutaneous lupus erythematosus and to better understand cutaneous lupus erythematosus and associated health problems. Autoimmune disease such as lupus can greatly affect the quality of life. There are no Federal Drug Administration (FDA) approved treatments for people with CLE.

The study drug, anifrolumab, is already approved in the United States to treat adults with systemic lupus erythematosus (SLE), but it has not yet been approved by the FDA for use as an injection for CLE.

This study is for adults aged 18 to 70 years old with chronic or treatment-resistant cutaneous lupus erythematosus (CLE).

If you qualify and decide to participate, you will be asked to:

· Be in the research study for up to 71 weeks. You will be expected to attend the study clinic once every 4 weeks during the first 6 months of the study, with less frequent visits thereafter

· Attend all scheduled study visits

· Tell the study doctor if you are feeling bad or worse than before

· Follow the instructions of the study doctor

· Fill out your questionnaires completely and honestly

· Carry your participation card with you as long as you are in the study and show it to any medical staff that may be involved in your healthcare

· Do not start or stop any medications without checking with your study doctor and tell the study doctor if you have any changes in the medication you take during the study

· Follow directions for using, storing, and returning the study drug; only you should take the study drug

This is a study to investigate the efficacy and safety of amlitelimab by subcutaneous injection in participants with moderate-to-severe atopic dermatitis who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase inhibitor treatment

The purpose of this research is to measure clinical safety and efficacy of oral brepocitinib in adults with cutaneous sarcoidosis. In this study, two different doses (strengths) of brepocitinib will be compared to a placebo. This study is being done to determine how safe and effective brepocitinib is and if it works to help decrease the inflammation associated with cutaneous sarcoidosis. This study this is for 24 weeks (about 6 months).

The purpose of this research study is to evaluate the safety and efficacy of the study drug treatment in combination with visible light therapy in patients with cutaneous T-cell lymphoma when compared to placebo. The study drug, HyBryte, contains 0.25% hypericin. Hypericin is a known photodynamic agent (a drug that becomes activated by light) with potential to treat a variety of inflammatory skin diseases.